Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinomain situ

2002 ◽  
Vol 198 (4) ◽  
pp. 458-467 ◽  
Author(s):  
Werner Boecker ◽  
Roland Moll ◽  
Peter Dervan ◽  
Horst Buerger ◽  
Christopher Poremba ◽  
...  
Keyword(s):  
Progenitor Cell ◽  
Atypical Ductal Hyperplasia ◽  
Ductal Carcinomain Situ ◽  
Usual Ductal Hyperplasia ◽  
Ductal Hyperplasia ◽  
Carcinomain Situ

TP53 alterations in atypical ductal hyperplasia and ductal carcinomain situ of the breast

1996 ◽  
Vol 41 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Margaret Chitemerere ◽  
Tone Ikdahl Andersen ◽  
Ruth Holm ◽  
Frank Karlsen ◽  
Anne-Lise Børresen ◽  
...  
Keyword(s):  
Atypical Ductal Hyperplasia ◽  
Ductal Carcinomain Situ ◽  
Ductal Hyperplasia ◽  
Carcinomain Situ

High-Risk Breast Lesions

2017 ◽  
Author(s):  
Richard J Bleicher
Keyword(s):  
High Risk ◽  
Atypical Ductal Hyperplasia ◽  
Lobular Carcinoma ◽  
Breast Disease ◽  
Lobular Neoplasia ◽  
Radial Scar ◽  
Imaging Evaluation ◽  
Usual Ductal Hyperplasia ◽  
Ductal Hyperplasia ◽  
Papillary Lesions

Clinicians who treat breast disease deal with a variety of pathologic findings. Although there is often a focus on paradigms and data regarding malignant breast disease, benign breast disease ranges from that which requires no imaging, evaluation, or treatment to that which requires further testing to rule out concomitant cancer and ameliorate subsequent risk. This review discusses the most frequent types of high-risk lesions facing the breast practitioner, including atypical ductal hyperplasia, lobular neoplasia, radial scar, and papillary lesions. It is critical that the clinician understand the implications of each finding to advise about the risks associated with each of these entities, fully assess the need for further therapy, and mitigate the patient’s future risk.  This review contains 2 tables, and 69 references. Key words: atypical ductal hyperplasia, atypical lobular hyperplasia, lobular neoplasia, lobular carcinoma in situ, papillary lesions, pleomorphic, pseudoangiomatous stromal hyperplasia, radial scar, usual ductal hyperplasia

scholarly journals Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ

2016 ◽  
Vol 140 (7) ◽  
pp. 686-689 ◽  
Author(s):  
Anthony P. Martinez ◽  
Cynthia Cohen ◽  
Krisztina Z. Hanley ◽  
Xiaoxian (Bill) Li
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Atypical Ductal Hyperplasia ◽  
Low Grade ◽  
Usual Ductal Hyperplasia ◽  
Ductal Hyperplasia ◽  
Cytokeratin 5

Context.—High–molecular weight cytokeratins, such as cytokeratin 5 (CK5), are helpful to distinguish usual ductal hyperplasia (UDH) from atypical ductal hyperplasia (ADH) or low-grade ductal carcinoma in situ (DCIS). Few studies have looked at combining CK5 with estrogen receptor (ER) to differentiate UDH from ADH. Objective.—To evaluate the expression pattern of CK5 and ER as single or combined markers to separate UDH from ADH and low-grade DCIS. Design.—A total of 23 ADH, 10 low-grade DCIS, and 32 UDH whole-tissue slides were stained for ER, CK5, progesterone receptor (PR), and Bcl-2. Nuclear staining of ER and PR was scored as diffuse (>80%), focal (10%–80%), or negative (<10%). Cytoplasmic staining of CK5 and Bcl-2 was scored as diffuse (>60%), focal (10%–60%), or negative (<10%). Differences in staining patterns were evaluated. Results.—For ER staining: 94% of ADH/DCIS cases showed a diffuse staining pattern, whereas none of the 32 UDH cases showed diffuse staining. For CK5 staining: 96% of ADH/DCIS cases were negative or focally positive, whereas all 32 UDH cases had diffuse staining. The combination of ER and CK5 increased the sensitivity (94% to 97%). For PR staining: 11 of 23 ADH cases (48%), 6 of 10 DCIS cases (60%), and 4 of 32 UDH cases (13%) showed diffuse staining. Bcl-2 staining showed no statistical significance (P = .73). Conclusions.—Although morphology remains the gold standard, ER and CK5 are useful makers to differentiate UDH from ADH. Progesterone receptor staining may have limited value, and Bcl-2 staining is not useful.

High-Risk Breast Lesions

2017 ◽  
Author(s):  
Richard J Bleicher
Keyword(s):  
High Risk ◽  
Atypical Ductal Hyperplasia ◽  
Lobular Carcinoma ◽  
Breast Disease ◽  
Lobular Neoplasia ◽  
Radial Scar ◽  
Imaging Evaluation ◽  
Usual Ductal Hyperplasia ◽  
Ductal Hyperplasia ◽  
Papillary Lesions

Clinicians who treat breast disease deal with a variety of pathologic findings. Although there is often a focus on paradigms and data regarding malignant breast disease, benign breast disease ranges from that which requires no imaging, evaluation, or treatment to that which requires further testing to rule out concomitant cancer and ameliorate subsequent risk. This review discusses the most frequent types of high-risk lesions facing the breast practitioner, including atypical ductal hyperplasia, lobular neoplasia, radial scar, and papillary lesions. It is critical that the clinician understand the implications of each finding to advise about the risks associated with each of these entities, fully assess the need for further therapy, and mitigate the patient’s future risk.  This review contains 2 tables, and 69 references. Key words: atypical ductal hyperplasia, atypical lobular hyperplasia, lobular neoplasia, lobular carcinoma in situ, papillary lesions, pleomorphic, pseudoangiomatous stromal hyperplasia, radial scar, usual ductal hyperplasia

Sign in / Sign up

Export Citation Format

Share Document